SIZE XSSIZE SMSIZE MDSIZE LG

HOPA is committed providing high quality education that is strongly integrated with HOPA’s core passion to support pharmacy practitioners and promote and advance Hematology/Oncology Pharmacy to optimize the care of individuals affected by cancer. HOPA strives to become the destination of choice for quality education focused on creating competent hematology/oncology pharmacists with sound domain knowledge, skills and managerial acumen.  Below is the full spectrum of education offerings – you may also sort by content area, date, delivery method, and if it offers BCOP recertification credit.

BCOP Updates Course

Please Note:  The education will be released in July.

The BCOP Oncology Pharmacy Updates Course is an educational program designed for the practicing advanced level Board Certified Oncology Pharmacist. Covering new and ongoing therapeutic developments that have emerged within the last three years, the Updates Course will provide you with up-to-date information, including recently published or ongoing studies from the past 2–3 years that you can immediately apply to your practice. Up to 10 hours of BCOP and ACPE credit are available for this education.

New in 2020: BCOP and ACPE credit will remain available for up to 1 year following its release.

Highlights

  • Learn about promising research and new treatment regiments.
  • Get clinical updates on treatment of tumor types and new supportive care therapies.
  • Find an overview of common clinical and technical issues in the hematology/oncology clinical setting.

2020 BCOP Updates Course

  • Module 1 – Updates in the Management of Endocrine Tumors – Kate Jeffers, PharmD MHA BCOP (1.0 BCOP/ACPE)
  • Module 2 – New Therapies for Rare Hematologic Disorders – Dwight (David) Eplin, PharmD BCOP (1.5 BCOP/ACPE)
  • Module 3 – HIV/AIDS and Concomitant Cancer Diagnosis – Timothy Y. Mok, PharmD BCPS BCOP (1.0 BCOP/ACPE)
  • Module 4 – Updates in Small Cell Lung Cancer and Small Cell Carcinoma of the Ovary, Hypercalcemic Type – Whitney E. Lewis, PharmD BCOP (1.0 BCOP/ACPE)
  • Module 5 – Advances in Bladder Cancer Management – Christine Cambareri, PharmD BCPS BCOP (1.0 BCOP/ACPE)
  • Module 6 – Review of the Treatment of Light-Chain Amyloidosis – David M. Hughes, PharmD BCOP (1.0 BCOP/ACPE)
  • Module 7 – Pediatrics (1.0 BCOP/ACPE)
  • Module 8 – Molecular BRAF Signaling Pathways – Anand Shah, PharmD BCOP BCPS (1.0 BCOP/ACPE)
  • Module 9 – Updates in Chronic Lymphocytic Leukemia (CLL) – Sarah Hopps Schmidt, PharmD BCOP BCPS (1.5 BCOP/ACPE)

Each module or session will include a recording of the faculty presenting their topic, a pre-test and BCOP post-test. You may choose to complete all or select individual sessions, receiving BCOP credit for each completed module when you achieve a passing score.

HOPA Member Price: $225
Non-Member Price: $325

Purchase now

The 2020 BCOP Oncology Pharmacy Updates Course is also a part of the 2020 BCOP Complete Program Bundle. Purchase the suite of all 2020 BCOP education, including BCOP Annual Conference and BCOP Self Study, and save. 

HOPA Member Price: $700
Non-Member Price: $1030

Purchase now


2019 BCOP Updates Course

Available for purchase through December 24, 2019. Credit available through December 31, 2019.

Each module or session will include a recording of the faculty presenting their topic, a pre-test and BCOP post-test. You will also have the opportunity to pre-submit questions to the faculty via This email address is being protected from spambots. You need JavaScript enabled to view it. or attend their designated Office Hours where you will have the opportunity to ask your own questions and hear answers to the pre-submitted questions.

If you are unable to attend these Office Hours, you will be able to listen to these sessions as well in HOPA's My Education Library. You may choose to complete all or select individual sessions, receiving BCOP credit for each completed module which achieves a passing score.

HOPA Member Price: $225
Non-Member Price: $325

Available for purchase through December 24, 2019. Credit available through December 31, 2019.

Purchase now

The 2019 BCOP Updates Course is also a part of the 2019 BCOP Program Bundle. If you've already purchased the 2019 BCOP Program Bundle, you can access your Updates Course in My Education Library.

Accreditation Statement:

logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE test must be completed by December 31, 2019.

education speaker bpslogo The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Test must be completed by December 31, 2019.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.

xs
sm
md
lg